Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
181.35M | 185.24M | 191.49M | 206.28M | 194.60M | 176.90M | Gross Profit |
85.20M | 91.47M | 30.56M | 140.58M | 144.33M | 127.61M | EBIT |
5.13M | 2.09M | 3.36M | 15.11M | 13.52M | -1.20M | EBITDA |
-28.32M | 12.05M | 9.89M | 22.48M | 15.20M | -13.53M | Net Income Common Stockholders |
-30.52M | -30.30M | -1.57M | 36.78M | 14.97M | -1.69M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
18.36M | 9.93M | 18.36M | 10.36M | 11.91M | 29.41M | Total Assets |
131.07M | 101.78M | 122.76M | 119.98M | 107.86M | 119.50M | Total Debt |
28.51M | 24.60M | 28.51M | 22.32M | 30.77M | 55.06M | Net Debt |
10.14M | 14.66M | 10.14M | 11.96M | 18.86M | 25.65M | Total Liabilities |
111.22M | 80.09M | 102.90M | 101.18M | 122.85M | 162.90M | Stockholders Equity |
19.86M | 21.69M | 19.86M | 18.81M | -14.99M | -43.40M |
Cash Flow | Free Cash Flow | ||||
-4.39M | -6.73M | 7.67M | 22.99M | -4.81M | -10.54M | Operating Cash Flow |
-1.80M | -2.99M | 10.48M | 28.79M | -1.76M | -7.84M | Investing Cash Flow |
-3.32M | -3.74M | -2.31M | -11.49M | -2.90M | -775.00K | Financing Cash Flow |
4.15M | -419.00K | -3.22M | -15.82M | -13.41M | 7.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $708.68M | 12.71 | 9.10% | 7.58% | -2.69% | 61.73% | |
66 Neutral | $4.51B | 12.29 | 5.40% | 3.67% | 4.15% | -12.21% | |
58 Neutral | $26.24M | ― | -12.15% | ― | 17.04% | -2188.42% | |
57 Neutral | $87.36M | ― | -16.55% | ― | -2.67% | 21.65% | |
46 Neutral | $32.77M | ― | -147.49% | ― | -4.46% | -3053.30% | |
41 Neutral | $37.82M | ― | -123.16% | ― | -15.07% | 33.40% | |
$5.20M | ― | ― | ― | ― |
At the Harte Hanks 2025 Annual Meeting of Stockholders held on May 22, 2025, stockholders voted on key governance and operational matters. Four board nominees were elected to serve until the 2026 annual meeting, and the compensation of named executive officers was approved on a non-binding advisory basis. Additionally, the selection of Wolf & Company P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (HHS) stock is a Buy with a $17.50 price target. To see the full list of analyst forecasts on Harte-Hanks stock, see the HHS Stock Forecast page.